Proceedings of the National Academy of SciencesSystems BiologyPeer-reviewed journal article
Logic-based mechanistic machine learning on high-content images reveals how drugs differentially regulate cardiac fibroblasts
Anders R. NelsoniD, Steven L. M. ChristianseniD, Kristen M. NaegleiD, Jeffrey J. SaucermaniD
Abstract
Fibroblasts are essential regulators of extracellular matrix deposition following cardiac injury. These cells exhibit highly plastic responses in phenotype during fibrosis in response to environmental stimuli. Here, we test whether and how candidate anti-fibrotic drugs differentially regulate measures of cardiac fibroblast phenotype, which may help identify treatments for cardiac fibrosis. We conducted a high content microscopy screen of human cardiac fibroblasts treated with 13 clinically relevant drugs in the context of TGF{beta} and/or IL-1{beta}, measuring phenotype across 137 single-cell features. We used the phenotypic data from our high content imaging to train a logic-based mechanistic machine learning model (LogiMML) for fibroblast signaling. The model predicted how pirfenidone and Src inhibitor WH-4-023 reduce actin filament assembly and actin-myosin stress fiber formation, respectively. Validating the LogiMML model prediction that PI3K partially mediates the effects of Src inhibition, we found that PI3K inhibition reduces actin-myosin stress fiber formation and procollagen I production in human cardiac fibroblasts. In this study, we establish a modeling approach combining the strengths of logic-based network models and regularized regression models, apply this approach to predict mechanisms that mediate the differential effects of drugs on fibroblasts, revealing Src inhibition acting via PI3K as a potential therapy for cardiac fibrosis. SignificanceCardiac fibrosis is a dysregulation of the normal wound healing response, resulting in excessive scarring and cardiac dysfunction. As cardiac fibroblasts primarily regulate this process, we explored how candidate anti-fibrotic drugs alter the fibroblast phenotype. We identify a set of 137 phenotypic features that change in response to drug treatments. Using a new computational modeling approach termed logic-based mechanistic machine learning, we predict how pirfenidone and Src inhibition affect the regulation of the phenotypic features actin filament assembly and actin-myosin stress fiber formation. We also show that inhibition of PI3K reduces actin-myosin stress fiber formation and procollagen I production in human cardiac fibroblasts, supporting a role for PI3K as a mechanism by which Src inhibition may suppress fibrosis.
- organism: human
- assay: imaging
- research focus: differential expression
- research focus: cell type annotation
- research focus: drug response / drug discovery
- research focus: gene regulatory network inference
- approach: machine learning (classical)
- approach: statistical model
- Citations
- 19
- FWCI
- 5.39
- Field percentile
- top 3%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Circuit to target approach defines an autocrine myofibroblast loop that drives cardiac fibrosis
Shoval Miyara, Miri Adler, … Eldad Tzahor·Cell SystemsPeer-reviewed·Feb 18, 2025
- Inactivation of PRMT1 inhibits cardiac fibrosis via transcriptional regulation and perturbation of FBL activity in fibroblast-to-myofibroblast transition
Jiang Qian, Olan Jackson‐Weaver, … Jian Xu·bioRxiv·May 24, 2024
- Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure
J. M. Amrute, X. Luo, … K. Lavine·bioRxiv·Oct 17, 2022
- Fibroblast Mechanotransduction Network Predicts Targets for Mechano-Adaptive Infarct Therapies
Jesse D. Rogers, William J. Richardson·eLifePeer-reviewed·Feb 9, 2022
- The dual PPAR-α/δ agonist elafibranor attenuates TGF-β1-induced cardiac fibrosis through redox-metabolic and bioenergetic reprogramming in human cardiac models
Milena Paw, Lukas Minder, … Gabriela Kania·bioRxiv·Aug 21, 2026
- Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug screening
O. N. Mastikhina, B.-U. Moon, … S. S. Nunes·bioRxiv·Aug 14, 2019